Literature DB >> 20660663

Expression, purification, and characterization of Aspergillus fumigatus sterol 14-alpha demethylase (CYP51) isoenzymes A and B.

Andrew G S Warrilow1, Nadja Melo, Claire M Martel, Josie E Parker, W David Nes, Steven L Kelly, Diane E Kelly.   

Abstract

Aspergillus fumigatus sterol 14-α demethylase (CYP51) isoenzymes A (AF51A) and B (AF51B) were expressed in Escherichia coli and purified. The dithionite-reduced CO-P450 complex for AF51A was unstable, rapidly denaturing to inactive P420, in marked contrast to AF51B, where the CO-P450 complex was stable. Type I substrate binding spectra were obtained with purified AF51B using lanosterol (K(s), 8.6 μM) and eburicol (K(s), 22.6 μM). Membrane suspensions of AF51A bound to both lanosterol (K(s), 3.1 μM) and eburicol (K(s), 4.1 μM). The binding of azoles, with the exception of fluconazole, to AF51B was tight, with the K(d) (dissociation constant) values for clotrimazole, itraconazole, posaconazole, and voriconazole being 0.21, 0.06, 0.12, and 0.42 μM, respectively, in comparison with a K(d) value of 4 μM for fluconazole. Characteristic type II azole binding spectra were obtained with AF51B, whereas an additional trough and a blue-shifted spectral peak were present in AF51A binding spectra for all azoles except clotrimazole. This suggests two distinct azole binding conformations within the heme prosthetic group of AF51A. All five azoles bound relatively weakly to AF51A, with K(d) values ranging from 1 μM for itraconazole to 11.9 μM for fluconazole. The azole binding properties of purified AF51A and AF51B suggest an explanation for the intrinsic azole (fluconazole) resistance observed in Aspergillus fumigatus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660663      PMCID: PMC2944604          DOI: 10.1128/AAC.00316-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Substrate recognition sites in 14alpha-sterol demethylase from comparative analysis of amino acid sequences and X-ray structure of Mycobacterium tuberculosis CYP51.

Authors:  L M Podust; J Stojan; T L Poulos; M R Waterman
Journal:  J Inorg Biochem       Date:  2001-12-15       Impact factor: 4.155

2.  Identification, characterization, and azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae.

Authors:  Andrew G S Warrilow; Colin J Jackson; Josie E Parker; Timothy H Marczylo; Diane E Kelly; David C Lamb; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

3.  Ligand interactions with cytochrome P-450. I. Binding of primary amines.

Authors:  C R Jefcoate; J L Gaylor; R L Calabrese
Journal:  Biochemistry       Date:  1969-08       Impact factor: 3.162

4.  Structural basis of human CYP51 inhibition by antifungal azoles.

Authors:  Natallia Strushkevich; Sergey A Usanov; Hee-Won Park
Journal:  J Mol Biol       Date:  2010-02-10       Impact factor: 5.469

5.  Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors.

Authors:  J F Morrison
Journal:  Biochim Biophys Acta       Date:  1969

6.  Expression and functional characterization of cytochrome P450 26A1, a retinoic acid hydroxylase.

Authors:  Justin D Lutz; Vaishali Dixit; Catherine K Yeung; Leslie J Dickmann; Alex Zelter; Jayne E Thatcher; Wendel L Nelson; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2008-10-17       Impact factor: 5.858

7.  Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology.

Authors:  Aouatef Bellamine; Galina I Lepesheva; Michael R Waterman
Journal:  J Lipid Res       Date:  2004-08-16       Impact factor: 5.922

8.  Conservation in the CYP51 family. Role of the B' helix/BC loop and helices F and G in enzymatic function.

Authors:  Galina I Lepesheva; Cornelia Virus; Michael R Waterman
Journal:  Biochemistry       Date:  2003-08-05       Impact factor: 3.162

9.  Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.

Authors:  G A Lamaris; R Ben-Ami; R E Lewis; D P Kontoyiannis
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

10.  The construction and characterization of self-sufficient lanosterol 14-demethylase fusion proteins consisting of yeast CYP51 and its reductase.

Authors:  Yutaka Kitahama; Masashi Nakamura; Yuzo Yoshida; Yuri Aoyama
Journal:  Biol Pharm Bull       Date:  2009-04       Impact factor: 2.233

View more
  39 in total

1.  Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Jialin Liu; W David Nes; Michael R Waterman; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

2.  An overview about the medical use of antifungals in Portugal in the last years.

Authors:  Maria Manuel da S Azevedo; Luisa Cruz; Cidália Pina-Vaz; Acácio Gonçalves-Rodrigues
Journal:  J Public Health Policy       Date:  2016-02-11       Impact factor: 2.222

3.  Aspergillus fumigatus Afssn3-Afssn8 Pair Reverse Regulates Azole Resistance by Conferring Extracellular Polysaccharide, Sphingolipid Pathway Intermediates, and Efflux Pumps to Biofilm.

Authors:  Nanbiao Long; Liping Zeng; Guowei Zhong; Shanlei Qiao; Lei Li
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

4.  Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India.

Authors:  Cheshta Sharma; Rakesh Kumar; Nitin Kumar; Aradhana Masih; Dinesh Gupta; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A).

Authors:  Sara J Blosser; Robert A Cramer
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

6.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 7.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

8.  Azole drug import into the pathogenic fungus Aspergillus fumigatus.

Authors:  Brooke D Esquivel; Adam R Smith; Martin Zavrel; Theodore C White
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 9.  Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.

Authors:  Anna Dudakova; Birgit Spiess; Marut Tangwattanachuleeporn; Christoph Sasse; Dieter Buchheidt; Michael Weig; Uwe Groß; Oliver Bader
Journal:  Clin Microbiol Rev       Date:  2017-10       Impact factor: 26.132

10.  An invisible threat: mutation-mediated resistance to triazole drugs in Aspergillus.

Authors:  Cau D Pham; Shawn R Lockhart
Journal:  Curr Fungal Infect Rep       Date:  2012-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.